Inhibikase Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Inhibikase Therapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 111% to $260,500. Profit margin reached -7305%. Total operating expenses were $6,731,944.
Profit Margin
| 2017 | 2.06M | -436.07K | -21.16% |
|---|---|---|---|
| 2018 | 4.04M | -2.15M | -53.27% |
| 2019 | 1.12M | -5.74M | -511.95% |
| 2020 | 698.46K | -2.87M | -411.94% |
| 2021 | 3.10M | -14.80M | -477.52% |
| 2022 | 123.44K | -17.90M | -14505.22% |
| 2023 | 260.5K | -19.02M | -7304.75% |
IKT Income Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue | 260.5K | 123.44K | 3.10M | 698.46K | 1.12M | 4.04M | 2.06M |
Cost of revenue | 13.61M | 6.72K | 11.35M | 893.80K | 2.55M | 0 | 1.75M |
Gross profit | -13.35M | 116.71K | -8.25M | -195.33K | -1.42M | 4.04M | 305.24K |
Operating exp. | |||||||
Research and development | 13.61M | 12.03M | 11.35M | 893.80K | 2.55M | 3.64M | 1.75M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 6.73M | 18.12M | 14.76M | 2.81M | 5.69M | 2.12M | 2.46M |
Operating income | -20.08M | -18.12M | -14.76M | -2.81M | -5.69M | -2.12M | -405.13K |
Other income (expenses), net | 1.06M | 74.45K | -19.92K | -29.40K | -24.83K | -30.33K | -30.94K |
Income before tax | -19.02M | -18.05M | -14.78M | -2.84M | -5.72M | -2.15M | -436.07K |
Income tax expense | 0 | -148.90K | 19.92K | 29.40K | 24.83K | 0 | -405.13K |
Net income | -19.02M | -17.90M | -14.80M | -2.87M | -5.74M | -2.15M | -436.07K |
Earnings per share | |||||||
Basic EPS | -3.57 | -4.26 | -4.88 | -1.72 | -3.34 | -1.61 | -0.25 |
Diluted EPS | -3.57 | -4.26 | -4.88 | -1.72 | -3.34 | -1.61 | -0.25 |
| Data source | Data source | Data source | Data source |